Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide - Targets for drug development?

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 66, Issue 2-3, 2002, Pages 193-200

  Fowler, C J ^a   Jacobsson, S O P ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; FATTY ACID AMIDASE; FLUORESCEIN DERIVATIVE; METHANANDAMIDE; N (2 METHYL 4 HYDROXYPHENYL)ARACHIDONOYLAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; PALMIDROL; RIMONABANT; SKM 4 45 1; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; AMIDE; CANNABINOID; ENDOCANNABINOID; PALMITIC ACID DERIVATIVE;

ANIMAL CELL; CELL METABOLISM; DIFFUSION; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; ENZYME METABOLISM; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR TRANSPORT; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; REVIEW; TEMPERATURE SENSITIVITY; TRANSPORT KINETICS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ARACHIDONIC ACIDS; BIOLOGICAL TRANSPORT; CANNABINOIDS; DRUG DESIGN; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; MOLECULAR STRUCTURE; PALMITIC ACIDS; POLYUNSATURATED ALKAMIDES;

EID: 0036019387     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2001.0357     Document Type: Article

References (57)

1. The palmitoylethanolamide and oleamide enigmas: Are these two fatty acid amides cannabimimetic
2. The endocannabinoid system as a target for therapeutic drugs
3. Endocannabinoids control spasticity in a multiple sclerosis model
4. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
5. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes
6. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase
7. Formation and inactivation of endogenous cannabinoid anandamide in central neurons
8. Mechanisms of endocannabinoid inactivation: Biochemistry and pharmacology
9. Functional role of high-affinity anandamide transport, as revealed by selective inhibition
10. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes
11. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion
12. Anandamide hydrolysis by human cells in culture and brain
13. Structural determinants for recognition and translocation by the anandamide transporter
14. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells
15. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors
16. The cellular uptake of anandamide is coupled to its breakdown by fatty acid amide hydrolase (FAAH)
17. Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: Comparison with anandamide
18. Structure-activity relationships among N-arachidonoylethanolamine (anandamide) head group analogues for the anandamide transporter
19. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide
20. AM404 and inhibitors of fatty acid amide hydrolase prevent anandamide uptake and metabolism in SK-N-AS cells
21. Anandamide uptake by human endothelial cells and its regulation by nitric oxide
22. Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors
23. Unsaturated long-chain N-acyl-vanillylamides (N-AVAMs): Vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors
24. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase
25. (R)-methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability
26. Structure-activity relationship for the endogenous cannabinoid, anandamide and certain of its analogues at vanilloid receptors in transfected cells and vas deferens
27. 2 receptor responses by an anandamide transport inhibitor
28. Anandamide uptake is coupled to its metabolism by FAAH
29. Arachidonoyl phosphonofluoridates as cannabinoid receptor ligands and FAAH inhibitors
30. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide
31. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages
32. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: Connections with anandamide
33. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol
34. Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor
35. Metabolism of anandamide and 2-arachidonoylglycerol: An historical overview and some recent developments
36. N-acylethanolamine phospholipid metabolism in normal and ischemic rat brain
37. Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis
38. + cells
39. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration
40. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
41. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat
42. Potentiation of anandamide hypotension by the transport inhibitor, AM404
43. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404
44. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide
45. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity
46. Pharmacological effects in mice of anandamide and its related fatty acid ethanolamides, and enhancement of cataleptogenic effect of anandamide by phenylmethylsulfonyl fluoride
47. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
48. Fatty acid amide hydrolase: Biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamade, and oleamide
49. The anandamide transport inhibitor AM404 activates vanilloid receptors
50. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism
51. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: Inhibitors of anandamide uptake with negligible capsaicin-like activity
52. Design and synthesis of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors
53. 2 cannabinoid, as potential ligands for the cannabinoid receptor
54. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids: Relative involvement of cannabinoid and vanilloid receptors
55. Anandamide activates peripheral nociceptors in normal and arthritic knee joints
56. An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonyl-glycerol cannabinoid activity
57. Synthesis and characterization of a fluorescent substrate for the N-arachidonoylethanolamine (anandamide) transmembrane carrier